Immunology needs a reorg - Clinical Trial Manager bei Merck: Mitarbeiterbewertung

2.0
15. Jan. 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Some really talented people, pay, benefits

Kontras

Middle management who came in from other companies, Program Lead, to Sr. Program Leads need to be phased out in Immunology. They are toxic, they don't do their jobs and have made this place a revolving door. We have lost some really great talent due to the nonsense of this department.

Mehr Bewertungen zu Merck entdecken

5.0
11. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Amazing to work and smart people to work around.

Kontras

Not sponsoring in the US

4.0
2. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Over my tenure, I had the opportunity to work alongside highly talented and mission-driven colleagues dedicated to improving patient outcomes. The organization provided exposure to cross-functional collaboration, leadership development opportunities, and meaningful work supporting healthcare providers, patients, and community stakeholders. I appreciated the company's commitment to innovation, professional growth, and serving patients through scientific advancement.

Kontras

Like many large organizations, priorities and organizational structures evolved over time, which occasionally created uncertainty and changes in responsibilities. Decision-making processes could sometimes be complex due to the size of the organization, and navigating multiple layers of stakeholders occasionally impacted speed and execution.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle